Update Tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for The
Total Page:16
File Type:pdf, Size:1020Kb
Update tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Am j trop med hyg. 2020. 2. Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy. Ahn SJ, Joung J, Lee BR. American journal of ophthalmology. 2020;209:35-44. http://dx.doi.org/10.1016/j.ajo.2019.09.008. Epub 2019 Sep 14. 3. COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. J clin epidemiol. 2020. 4. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. Bauman JL, Tisdale JE. Pharmacotherapy. 2020. 5. Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials. Chang R, Sun W-Z. medRxiv. 2020:2020.04.18.20071167. 6. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Int J Antimicrob Agents. 2020:105932-. 7. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Cui C, Zhang M, Yao X, Tu S, Hou Z, Jie En VS, et al. Acta Pharmaceutica Sinica B. 2020. 8. Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia? Could It Be A Prophylactic Drug? Deniz O. 2020. 9. Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19). Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz A, Kakavand H, et al. Journal of cardiovascular pharmacology. 2020. 10. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. Arthritis care & research. 2019;71(10):1326-35. http://dx.doi.org/10.1002/acr.23759. Epub 2019 Aug 30. 11. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19). Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. The American Journal of Tropical Medicine and Hygiene. 2020. 12. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Fantini J, Di Scala C, Chahinian H, Yahi N. Int J Antimicrob Agents. 2020:105960-. 13. Chloroquine and hydroxychloroquine in covid-19. Ferner RE, Aronson JK. BMJ. 2020;369:m1432-m. 14. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. Fihn SD, Perencevich E, Bradley SM. JAMA Netw Open. 2020;3(4):e209035-e. 15. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes. Funck-Brentano C, Salem J-E, Nguyen LS, Drici M-D, Roden DM. Arch Cardiovasc Dis. 2020. 16. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Gao J, Hu S. Bioscience trends (Online). 2020. 17. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. Gbinigie K, Frie K. 2020. 18. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Guastalegname M, Vallone A. Clin infect dis. 2020. 19. COVID-19 and diabetes: Knowledge in progress. Hussain A, Bhowmik B, do Vale Moreira NC. Diabetes Research and Clinical Practice. 2020;162. 20. Hydroxy-CHLOROQUINE: THE CHEMOPROPHYLAXIS OF MALARIA AND COVID-19. Hussain I. 21. Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient. Ishiguro Y, Muro Y, Murase C, Takeichi T, Kono M, Adachi R, et al. The Journal of dermatology. 2019;46(10):e356-e7. http://dx.doi.org/10.1111/1346-8138.14905. Epub 2019 May 3. 22. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Jakhar D, Kaur I. Nat med. 2020. 23. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Juurlink DN. CMAJ. 2020. 24. Ultrasonography of articular and periarticular structures as a relapse predictor in patients with clinically remitted rheumatoid arthritis. Karami M, Mohammadzadeh Z, Ebrahimian S, Moradi M, Zahra S. Indian Journal of Rheumatology. 2020;15(1):17-22. 25. Myths and Facts: Chloroquine May Be A Potential Supportive/Therapeutic Drug in COVID-19 Treatment. Kashif M, Aamir M, Minhas S, Tahir R, Jahan S, Afzal N. 2020. 26. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19). Keshtkar-Jahromi M, Bavari S. Am j trop med hyg. 2020. 27. Safety review of 42 cases of COVID-19 treated with low-dose chloroquine. Li L, Zhou B, Zhang J, Liu Y, Hong W, Jian F, et al. Journal. 2020(Issue). 28. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Cell discovery. 2020. 29. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. medRxiv. 2020:2020.04.16.20065920. 30. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? Marmor MF. Am j ophthalmol. 2020. 31. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. Mégarbane B. Clin Toxicol (Phila). 2020:1-2. 32. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Millán-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. Annals of Clinical Microbiology and Antimicrobials. 2020;19(1):16. 33. An algorithm for managing QT prolongation in Coronavirus Disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Mitra RL, Greenstein SA, Epstein LM. HeartRhythm Case Reports. 2020. 34. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. Ann rheum dis. 2020. 35. International Standards for Neurological Classification of Spinal Cord Injury: factors influencing the frequency, completion and accuracy of documentation of neurology for patients with traumatic spinal cord injuries. Osunronbi T, Sharma H. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie. 2019;29(8):1639-48. http://dx.doi.org/10.1007/s00590-019-02502-7. Epub 2019 Jul 19. 36. The alteration of stress-related physiological parameters after probiotics administration in oral surgeons with different degrees of surgical experience. Pacifici A, Pacifici L, Nuzzolese M, Cascella G, Ballini A, Santacroce L, et al. La Clinica terapeutica. 2020;171(3):e197-e208. http://dx.doi.org/10.7417/CT.2020.2214. 37. Hydroxychloroquine for the Treatment of COVID-19: Evidence, Possible Mode of Action and Industrial Supply of the Drug. Pagliaro M, Meneguzzo F. 2020. 38. Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. Pereira BB. J Toxicol Environ Health B Crit Rev. 2020:1-5. 39. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Principi N, Esposito S. The Lancet Infectious Diseases. 2020. 40. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring. Ramireddy A, Chugh HS, Reinier K, Ebinger J, Park E, Thompson M, et al. medRxiv. 2020:2020.04.22.20075671. 41. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Rathi S, Ish P, Kalantri A, Kalantri S. The Lancet Infectious Diseases. 2020. 42. Delirium Cafe: interactive learning to enhance delirium care. Roitto HM, Aalto UL, Soderling R, Laakkonen ML, Ohman H. European geriatric medicine. 2020;11(1):113-6. http://dx.doi.org/10.1007/s41999-019-00283-0. Epub 2020 Jan 10. 43. Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. Saqrane S, El Mhammedi MA. New Microbes and New Infections. 2020. 44. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Sarayani A, Cicali B, Henriksen CH, Brown JD. Res soc adm pharm. 2020. 45. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Shah S, Das S, Jain A, Misra DP, Negi VS. Int j rheum dis. 2020. 46. Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Ghasemian R, et al. medRxiv. 2020:2020.04.14.20065276. 47. Chloroquine paradox may cause more damage than help fight COVID-19. Sharma A. Microbes and Infection. 2020. 48. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Diabetes Metab Syndr. 2020;14(3):241-6. 49. Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Cochrane Database of Systematic Reviews. 2020(4). 50. Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.